ACTT Trial Results Indicate Remdesivir’s Efficacy Against Covid-19
The National Institutes of Health released interim #data from the Phase 3 ACTT trial, which explores #remdesivir for the treatment of #Covid19. Interim findings show remdesivir decreased the patients’ recovery time by 31% over placebo (see link below).
Gayathri Raghupathy, Ph.D. provides insight on these results, stating that “while it may not be a cure, these results are very promising and can help advance the fight against Covid-19.”
The image below outlines the timeline and details of the #clinicaltrial.
#publichealth #publicawareness #COVID_19 #coronavirus #drugdevelopment #clinicaltrials #Kognitic #covid19research #covid19testing #pandemic #publichealthemergency #knowledgesharing #knowledge #Gilead
